Q3 2025 13F Holders as of 30 Sep 2025
-
Type / Class
-
Equity / COM
-
Number of holders
-
38
-
Total 13F shares, excl. options
-
4,341,662
-
Shares change
-
+799,699
-
Total reported value, excl. options
-
$7,702,477
-
Value change
-
+$1,416,796
-
Number of buys
-
23
-
Number of sells
-
-9
-
Price
-
$1.77
Significant Holders of Gain Therapeutics, Inc. - COM (GANX) as of Q3 2025
45 filings reported holding GANX - Gain Therapeutics, Inc. - COM as of Q3 2025.
Gain Therapeutics, Inc. - COM (GANX) has 38 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 4,341,662 shares
.
Largest 10 shareholders include JONES FINANCIAL COMPANIES LLLP (676,822 shares), DME Capital Management, LP (566,130 shares), VANGUARD GROUP INC (534,352 shares), CITADEL ADVISORS LLC (373,558 shares), GEODE CAPITAL MANAGEMENT, LLC (344,146 shares), Cambridge Investment Research Advisors, Inc. (318,645 shares), MARSHALL WACE, LLP (175,107 shares), MORGAN STANLEY (155,675 shares), UBS Group AG (140,677 shares), and RENAISSANCE TECHNOLOGIES LLC (126,100 shares).
This table shows the top 38 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.